Sampled Selected for Key Role in National Cancer Initiative
Sampled Selected for a Key Contractor Role in Cancer Research
Sampled, an integrated analytical biorepository and multiomics company, is thrilled to announce its selection as a vital contributor to the Genome Characterization program by the National Cancer Institute (NCI). This esteemed contract positions Sampled as a significant player in advancing cutting-edge cancer research and genomic discovery, with a funding ceiling reaching $150 million.
Participation Across Four Critical Contract Pools
As part of this award, Sampled will actively engage in all four specified contract pools, utilizing its advanced technologies and expert knowledge to provide comprehensive genomic solutions. Each pool is designed to tackle different aspects of cancer research, utilizing various cutting-edge techniques.
DNA Sequencing Pool
The first pool focuses on DNA Sequencing, where Whole Genome Sequencing and Whole Exome Sequencing will be employed using DNA extracted from both FFPE and fresh frozen samples. This initiative aims to support researchers in obtaining a thorough understanding of cancer biology by identifying key mutations, structural variations, and genetic abnormalities. These insights are crucial for advancing precision oncology and discovering novel therapeutic targets, which will support large-scale cancer genomic studies.
RNA Sequencing Pool
In the RNA Sequencing pool, RNAseq and microRNAseq methodologies will be used for transcriptomic analysis. By utilizing RNA extracted from relevant sample types, researchers will analyze gene expression patterns and regulatory pathways. This chromatographic assessment is essential for understanding how genetic changes affect tumor development and behavior and will contribute significantly to identifying biomarkers and studying the interactions within the tumor microenvironment.
Epigenome Characterization Pool
The third pool centers on Epigenome Characterization, employing methylation and chromatin accessibility techniques. These analyses will utilize both array and sequencing-based assays to investigate critical changes that drive cancer progression. By examining methylation patterns and chromatin modifications, researchers will gain valuable insight into therapeutic resistance.
Single Cell/Spatial Characterization Pool
The final pool focuses on Single Cell and Spatial Characterization. This involves utilizing Single-cell RNA, ATAC-seq, and advanced spatial analyses to create detailed maps of tumor heterogeneity. By analyzing individual cells and their interactions, this pool aims to study treatment resistance and advance immunotherapy strategies, personalizing cancer care for better outcomes.
Management Insights on the Contract
Sampled's Sr Director of Government and Public Sector, Greg Morrissey, expressed pride in the company's selection for the contract. He noted that participation across all four pools demonstrates Sampled's robust capabilities in supporting the scientific community's quest to uncover cancer's complexities and drive precision medicine forward.
Meanwhile, the company's Chief Scientific Officer, Shareef Nahas, emphasized the significance of this partnership with the NCI, stating that it will allow Sampled to contribute directly to oncology research efforts and accelerate the discovery of new cancer therapies. This collaboration aligns with Sampled's overarching mission to enhance human health and medical advancements through comprehensive genomic insights.
About Sampled
Sampled is a fully integrated laboratory and biorepository that offers industry-leading storage, sample management, and multiomics services. Established in 1999 and originally known as RUCDR Infinite Biologics at Rutgers University, Sampled operates accredited laboratories in both the United States and the United Kingdom. The company prides itself on providing the highest quality sample processing and analytical services, which empower researchers to achieve new breakthroughs in health sciences.
Media Contact
For media inquiries, please contact Caroline Mitchell, Director of Content & Creative Strategy, at +1 732-273-0699.
Frequently Asked Questions
What is Sampled's role in the National Cancer Institute's program?
Sampled has been selected as a principal contractor for the Genome Characterization program, providing vital genomic solutions across four contract pools.
What are the types of analyses Sampled will perform?
Sampled will conduct DNA sequencing, RNA sequencing, epigenome characterization, and single-cell/spatial characterization.
Why is this contract significant for cancer research?
This contract allows Sampled to contribute to crucial advancements in cancer genomics, supporting new discoveries that can improve patient outcomes.
How can the research community benefit from Sampled's contributions?
Sampled's innovative approaches will provide researchers with high-quality data and insights that can lead to breakthroughs in cancer therapy.
What is Sampled's commitment to quality?
Sampled is dedicated to delivering the highest quality services and solutions that enable new discoveries, enhancing the overall research landscape.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.